StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) company profile

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

About Inhibikase Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company that develops therapeutics designed to modify the course of cardiopulmonary diseases. The company focuses primarily on treatments for pulmonary arterial hypertension, an orphan disease marked by elevated pulmonary vascular resistance and vascular remodeling. Its primary product candidate is IKT-001, an oral prodrug of imatinib designed to minimize gastrointestinal adverse effects by exhibiting lower inhibitory activity at target tyrosine kinases such as c-Kit. As a clinical-stage entity, the company does not currently sell commercial products to end customers, but its pipeline targets patients suffering from pulmonary arterial hypertension.

The company's clinical operations include a two-part adaptive Phase 3 study known as IMPROVE-PAH, which spans approximately 180 planned clinical trial sites internationally. The company maintains principal executive offices located in Wilmington, Delaware. In addition, it operates corporate subsidiaries that include IKT Securities Corporation in Massachusetts and CorHepta Pharmaceuticals, Inc. in Delaware.

Summary of the business section of Inhibikase Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Inhibikase Therapeutics, Inc.
Headquarters
Wilmington, DE
Address
1000 N. West Street, Suite 1200 19801
Phone
(302) 295-3800
Employees
35, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
CohnReznick LLP, Holmdel, New Jersey

Stock & identifiers

Ticker
IKT
Exchange
Nasdaq
IPO date
Dec 28, 2020
Shares outstanding
140M, Aug 4, 2026
Public float
$127.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-6 reverse, Jun 30, 2023
SEC CIK
1750149
CUSIP
45719W205
ISIN
US45719W2052
FIGI
BBG005TP2339
Share class FIGI
BBG005TP2348
LEI
549300066CFEWOA17F12
EIN
26-3407249

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark T. IwickiChief Executive Officer, Director–
Milton H. WernerPresident and CEO, Director5,359,022
Christopher CabellPresident & Head of R&D676,564
David McIntyreChief Financial Officer10,285
Garth Lees-RolfeChief Financial Officer–
Scott M. WassermanDirector–
Dennis N. BermanDirector21,854
David CannerDirector–
Arvind KushDirector145,000
Vincent AurentzDirector510,596
Amit MunshiDirector403,176
Roberto BelliniDirector1,460,000
Roy Lester FreemanDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Mark Iwicki
$30.59M$29.68M$6.50M$161–
FY2025
Milton Werner
$803.06K$735.63K$6.50M$161–
FY2024$7.98M$7.60M$790.28K$256–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Mark Iwicki
Chief Executive Officer and Director
$624.21K$29.43M$532.50K–$30.59M–
Chris Cabell, M.D.
President and Head of Research and Development
$429.17K$6.76M$281.25K–$7.48M–
David McIntyre
Chief Financial Officer
$347.22K$4.90M$272.81K–$5.52M–
Milton H. Werner, Ph.D.
Former President and Chief Executive Officer
$728.98K$40.45K$31.54K$2.09K$803.06K-90%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 28, 2020
Offer price
$10.00
Securities offered
1,800,000
Gross proceeds
$18.00M
Exchange
Nasdaq
First trading day
Dec 28, 2020
First-day close
$9.34-6.6%
Lock-up ends (est.)
Jun 26, 2021

“The initial public offering price of our shares is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this Annual Report, we had thirty-five full time employees and no part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?